Progress in fumagillin synthesis

Pure and Applied Chemistry

Volumn 75, Issue 2-3, 2003, Pages 235-249

  Picoul, W ^a   Bedel, O ^a   Haudrechy, A ^a   Langlois, Y ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE;

CHEMICAL BOND; CLAISEN REARRANGEMENT; CONFERENCE PAPER; DIELS ALDER REACTION; DRUG SYNTHESIS; EPOXIDATION; INTERMETHOD COMPARISON; MITSUNOBU REACTION; PRIORITY JOURNAL; RING CLOSING METATHESIS; STEREOCHEMISTRY; TECHNIQUE;

EID: 0037317481     PISSN: 00334545     EISSN: None     Source Type: Journal    
DOI: 10.1351/pac200375020235     Document Type: Conference Paper

References (46)

1. T. E. Elbe and F. R. Hanson. Antibiot. Chemother. 1, 54 (1951).
2. H. P. Sigg and H. P. Weber. Helv. Chim. Acta 51, 1395 (1968).
3. H. Hatanaka, T. Kino, M. Hashimoto, Y. Tsurumi, A. Kuroda, H. Tanaka, T. Goto, M. Okuhara. J. Antibiot. 41, 999 (1988).
4. D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem, J. Folkman. Nature 348, 555 (1990).
5. E. J. Corey, A. Guzman-Perez, M. C. Noe. J. Am. Chem. Soc. 116, 12109 (1994) and references therein.
6. B. J. Dezube. J. Clin. Onc. 16, 1444 (1998).
7. (a) For other TNP-470 derivatives, see: S. Marui, T. Yamamoto, K. Sudo, H. Akimoto, S. Kishimoto. Chem. Pharm. Bull. 43, 588 (1995); (b) N. Sin, L. Meng, M. Q. W. Wang, J. J. Wen, W. G. Bornmann, C. M. Crews. Proc. Natl. Acad. Sci. USA 94, 6099 (1997); (c) E. C. Griffith, Z. Su, S. Niwayama, C. A. Ramsey, Y. H. Chang, J. O. Liu. Proc. Natl. Acad. Sci. USA 95, 15183 (1998); (d) C. K. Han, S. K. Ahn, N. S. Choi, R. K. Hong, S. K. Moon, H. K. Chun, S. J. Lee, J. W. Kim, C. I. Hong, D. Kim, J. H. Yoon, K. T. No. Bioorg. Med. Chem. 10, 39 (2000).
8. (a) For other TNP-470 derivatives, see: S. Marui, T. Yamamoto, K. Sudo, H. Akimoto, S. Kishimoto. Chem. Pharm. Bull. 43, 588 (1995); (b) N. Sin, L. Meng, M. Q. W. Wang, J. J. Wen, W. G. Bornmann, C. M. Crews. Proc. Natl. Acad. Sci. USA 94, 6099 (1997); (c) E. C. Griffith, Z. Su, S. Niwayama, C. A. Ramsey, Y. H. Chang, J. O. Liu. Proc. Natl. Acad. Sci. USA 95, 15183 (1998); (d) C. K. Han, S. K. Ahn, N. S. Choi, R. K. Hong, S. K. Moon, H. K. Chun, S. J. Lee, J. W. Kim, C. I. Hong, D. Kim, J. H. Yoon, K. T. No. Bioorg. Med. Chem. 10, 39 (2000).
9. (a) For other TNP-470 derivatives, see: S. Marui, T. Yamamoto, K. Sudo, H. Akimoto, S. Kishimoto. Chem. Pharm. Bull. 43, 588 (1995); (b) N. Sin, L. Meng, M. Q. W. Wang, J. J. Wen, W. G. Bornmann, C. M. Crews. Proc. Natl. Acad. Sci. USA 94, 6099 (1997); (c) E. C. Griffith, Z. Su, S. Niwayama, C. A. Ramsey, Y. H. Chang, J. O. Liu. Proc. Natl. Acad. Sci. USA 95, 15183 (1998); (d) C. K. Han, S. K. Ahn, N. S. Choi, R. K. Hong, S. K. Moon, H. K. Chun, S. J. Lee, J. W. Kim, C. I. Hong, D. Kim, J. H. Yoon, K. T. No. Bioorg. Med. Chem. 10, 39 (2000).
10. (a) For other TNP-470 derivatives, see: S. Marui, T. Yamamoto, K. Sudo, H. Akimoto, S. Kishimoto. Chem. Pharm. Bull. 43, 588 (1995); (b) N. Sin, L. Meng, M. Q. W. Wang, J. J. Wen, W. G. Bornmann, C. M. Crews. Proc. Natl. Acad. Sci. USA 94, 6099 (1997); (c) E. C. Griffith, Z. Su, S. Niwayama, C. A. Ramsey, Y. H. Chang, J. O. Liu. Proc. Natl. Acad. Sci. USA 95, 15183 (1998); (d) C. K. Han, S. K. Ahn, N. S. Choi, R. K. Hong, S. K. Moon, H. K. Chun, S. J. Lee, J. W. Kim, C. I. Hong, D. Kim, J. H. Yoon, K. T. No. Bioorg. Med. Chem. 10, 39 (2000).
11. W. T. Lowter, D. A. McMillen, A. M. Orville, B. W. Matthews. Proc. Natl. Acad. USA 95, 12153 (1998).
12. S. Liu, J. Widom, C. W. Kemp, C. M. Crews, J. Clardy. Science 282, 1324 (1998).
13. For a review concerning low-molecular-weight compound inhibitors of angiogenesis, see: A. Giannis and F. Rubsam. Angew. Chem., Int. Ed. Engl. 36, 588 (1997).
14. For a recent synthesis of oxa-fumagillin analog, see: J. E. Baldwin, P. G. Bulger, R. Marquez. Tetrahedron 58, 5442 (2002).
15. E. J. Corey and B. B. Snider. J. Am. Chem. Soc. 94, 2549 (1972).
16. D. Kim, S. K. Ahn, H. Bae, W. J. Choi, H. S. Kim. Tretrahedron Lett. 38, 4437 (1997).
17. D. F. Taber, T. E. Christos, A. L. Rheingold, I. A. Guzei. J. Am. Chem. Soc. 121, 5589 (1999).
18. J.-G. Boiteau, P. Van de Weghe, J. Eustache. Org. Lett. 3, 2737 (2001).
19. D. A. Vosburg, S. Veiler, E. J. Sorensen. Angew. Chem., Int. Ed. 38, 971 (1999).
20. M. Hutchings, D. Moffat, N. S. Simpkins. Synlett 661 (2001).
21. A. J. Birch and S. F. Hussain. J. Chem. Soc. 1473 (1969).
22. D. E. Cane and D. B. Mc Ilwaine. Tetrahedron Lett. 28, 6545 (1987).
23. J. Halasz, B. Podanyi, L. Vasvari-Debreczy, A. Szabo, F. Hadju, Z. Böcskei, J. Hegedus-Vajda, A. Gyorbiro, I. Hermecz. Tetrahedron 56, 10081 (2000).
24. However, in some fumagillin analogs, which displayed in vivo antitumor activity, the spiro epoxide is transformed into a hydroxy methylenesulfonium derivative, see ref. 7a.
25. For clarity, the fumagillin numbering has systematically been used.
26. For a model reaction, see: G. Büchi and J. E. Powell Jr. J. Am. Chem. Soc. 92, 3126 (1970).
27. For recent accounts of Claisen-Ireland rearrangements, see: (a) Y. Chai, S-p. Hong, H. A. Lindsay, C. McFarland, M. C. McIntosh. Tetrahedron 58, 2905 (2002); (b) D. Enders, M. Knopp, R. Schiffers. Tetrahedron: Asymmetry 7, 1847 (1996); (c) J. S. Panek, S. Schaus, C. E. Masse. Chemtracts: Org. Chem. 8, 238 (1995).
28. For recent accounts of Claisen-Ireland rearrangements, see: (a) Y. Chai, S-p. Hong, H. A. Lindsay, C. McFarland, M. C. McIntosh. Tetrahedron 58, 2905 (2002); (b) D. Enders, M. Knopp, R. Schiffers. Tetrahedron: Asymmetry 7, 1847 (1996); (c) J. S. Panek, S. Schaus, C. E. Masse. Chemtracts: Org. Chem. 8, 238 (1995).
29. For recent accounts of Claisen-Ireland rearrangements, see: (a) Y. Chai, S-p. Hong, H. A. Lindsay, C. McFarland, M. C. McIntosh. Tetrahedron 58, 2905 (2002); (b) D. Enders, M. Knopp, R. Schiffers. Tetrahedron: Asymmetry 7, 1847 (1996); (c) J. S. Panek, S. Schaus, C. E. Masse. Chemtracts: Org. Chem. 8, 238 (1995).
30. Alternatively, it was possible to prepare an enantiomeric lactone of 22 with an E-double bond on side chain. Rearrangement of this lactone could give rise to a diastereomer of 27 with natural configuration at C4 and unnatural at C3. Inversion of configuration at C3 as in previous syntheses could then be realized. However, the lengthy preparation of lactone 22 [26] was a major drawback for the use of this alternative.
31. W. Picoul. Ph.D. thesis, Université de Paris-Sud, Orsay, 18 January 2001.
32. For reviews on olefin metathesis, see: (a) A. Fürstner. Angew. Chem., Int. Ed. 39, 3012 (2000); (b) R. H. Grubbs and C. Sukbok. Tetrahedron 54, 4413 (1998).
33. For reviews on olefin metathesis, see: (a) A. Fürstner. Angew. Chem., Int. Ed. 39, 3012 (2000); (b) R. H. Grubbs and C. Sukbok. Tetrahedron 54, 4413 (1998).
34. Y. Ichikawa, K. Tsuboi, M. Isobe. J. Chem. Soc., Perkin Trans. 1 2791 (1994).
35. J. A. Macritchie, A. Silcock, C. L. Willis. Tetrahedron: Asymmetry 8, 3895 (1997).
36. 4 by the method described by Courtieu et al., see: [26] and I. Canet, A. Meddour, A. Lowenstein, J. M. Péchiné, J. Courtieu. J. Am. Chem. Soc. 117, 6520 (1995).
37. W. Picoul, R. Urchegui, A. Haudrechy, Y. Langlois. Tetrahedron Lett. 40, 4797 (1999).
38. E. I. Negishi, D. E. Van Horn, T. Yoshida. J. Am. Chem. Soc. 107, 6639 (1985).
39. (a) S. Ohira. Synth. Commun. 19, 561 (1989);
40. (b) S. Müller, B. Liepold, G. J. Roth, H. J. Bestmann. Synlett 521 (1996).
41. E. J. Corey, R. K. Bakshi, S. Shibata, C. P. Cheng, V. K. Singh. J. Am. Chem. Soc. 52, 5406 (1987).
42. Minor diastereomers were eliminated at this stage during ester purification.
43. (a) H. Ronneberg, G. Borch, R. Buchecker, N. Arpin, S. Liaaen-Jensen. Phytochemistry 21, 2087 (1982);
44. (b) S. Ohira, T. Ida, M. Moritani, T. Hasegawa. J. Chem. Soc., Perkin Trans. 1 293 (1998).
45. (a) M. Julia, S. Julia, R. Guégan. Bull. Soc. Chim. Fr. 1072 (1960);
46. (b) S. Brady, M. A. Ilton, W. S. Johnson. J. Am. Chem. Soc. 90, 2882 (1968).